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Abstract 22 
New psychoactive substances (NPS), often designed as (legal) substitutes to conventional illicit drugs, 23 
are constantly emerging in the drug market and being commercialized in different ways and forms. 24 
Their use continues to cause public health problems and is therefore of major concern in many 25 
countries. Monitoring NPS use, however, is arduous and different sources of information are required 26 
to get more insight of the prevalence and diffusion of NPS use. The determination of NPS in pooled 27 
urine and wastewater has shown great potential, adding a different and complementary light on this 28 
issue. However, it also presents analytical challenges and limitations that must be taken into account 29 
such as the complexity of the matrices, the high sensitivity and selectivity required in the analytical 30 
methods as a consequence of the low analyte concentrations as well as the rapid transience of NPS 31 
on the drug market creating a scenario with constantly moving analytical targets. Analytical 32 
investigation of NPS in pooled urine and wastewater is based on liquid chromatography hyphenated 33 
to mass spectrometry and can follow different strategies: target, suspect and non-target analysis. This 34 
work aims to discuss the advantages and disadvantages of the different data acquisition workflows 35 
and data exploration approaches in mass spectrometry, but also pays attention to new developments 36 
such as ion mobility and the use of in-silico prediction tools to improve the identification capabilities 37 
in high-complex samples. This tutorial gives an insight into this emerging topic of current concern, and 38 
describes the experience gathered within different collaborations and projects supported by key 39 
research articles and illustrative practical examples. 40 
 41 
Keywords 42 
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1. Introduction  45 
New psychoactive substances (NPS) are continually evolving and introduced in different ways in the 46 
drug market. The NPS retail market is characterized by its dynamic nature and the large number of 47 
substances covering a broad range of drug categories [1,2]. Whereas most NPS disappear after a short 48 
time, others seem to establish a niche market [2,3]. They are often introduced as legal substitutes for 49 
known controlled drugs, but also explored for their novel effect. Some substances have been known 50 
for years and are now misused for recreational purposes, but most NPS are newly synthesized with 51 
little or no safety data regarding their short or long-term toxicity. Furthermore, purity and composition 52 
of products containing NPS are often not known, which places users at an even higher risk compared 53 
to well-known conventional illicit drugs [1,2]. The NPS market is extremely diverse and differs between 54 
countries. Governments have responded in different ways to the NPS market, but have not been able 55 
to act upon all the NPS which have emerged in an effective way in terms of penalizing its supply and 56 
use [4]. Hence, NPS continue to cause public health problems [5,6] and challenge healthcare 57 
professionals, toxicologists and policymakers in terms of identification, prevention, treatment and 58 
control.  59 
The Early Warning Systems (EWS) established by the European Monitoring Centre for Drugs and Drug 60 
Addiction (EMCDDA), Europol and the United Nations Office of Drugs and Crime (UNODC) play a key 61 
role in collecting data on new NPS appearing on the market. This information together with indications 62 
of the health and social risks associated with these substances is pivotal to respond to the emergence 63 
of NPS [7]. Analytical chemistry has a prominent role in gathering more thorough data which allows 64 
to better understand the situation of NPS use in the population. To complement the existing sources 65 
of information and improve our knowledge about the categories and characteristics of NPS present 66 
on the market, the application of appropriate analytical strategies is of utmost importance.  67 
The discovery and characterization of new substances in commercially available products and drug 68 
seizures is an important source of information for EWS. Since reference standards for unambiguous 69 
confirmation of the identity are often not available, a combination of several techniques, such as 70 
nuclear magnetic resonance (NMR), liquid chromatography (LC) coupled to high resolution mass 71 
spectrometry (HRMS), gas chromatography mass spectrometry (GC-MS) and X-ray crystallography, is 72 
normally applied [8–11]. Although there is a correlation, the identification of new substances in seized 73 
products mainly gives information on the NPS available on the market rather than information on the 74 
prevalence of use. Therefore, the analysis of biological samples is needed, but this implies a different 75 
analytical strategy to deal with the complexity of the matrix and the low analyte concentrations 76 
normally present in the samples [12–14].  77 
4 / 44 
 
The analysis of biological samples can be considered a frontline in the detection of consumed NPS. 78 
Samples of individuals can be collected from, for example, hospital emergency rooms, drug testing 79 
campaigns or post-mortem examinations, where concentrations of some NPS in acute intoxications 80 
may be relatively high. This may facilitate the identification of hitherto unknown intoxicants by means 81 
of the abovementioned analytical techniques [3]. However, it does not give a full picture of NPS use 82 
within a community, rather individuals, and the analyses of many samples required to have a wider 83 
picture is time consuming and expensive. In contrast, pooled urine and urban wastewater can 84 
anonymously provide information of many people in one single aggregated sample. Although the 85 
dilution factor can be rather high in these matrices, for example dilution of the sample with urine of 86 
non-consumers or water used in households and industry, it has demonstrated its utility for 87 
community-wide monitoring of illicit drug use and showed possibilities for getting complementary 88 
insight into the consumption and diffusion of NPS use [15–20].  89 
Liquid chromatography hyphenated to tandem mass spectrometry instruments (LC-MS/MS) with 90 
triple quadrupole mass analyzers (QqQ) or hybrid HRMS/MS systems are the preferred analytical 91 
techniques that have the required high sensitivity and selectivity to deal with the challenges related 92 
to the screening of NPS in pooled urine and wastewater. Furthermore, the polar characteristics of 93 
most NPS and their metabolites, as well as the sample matrix, make them compatible with these 94 
techniques. This article aims to discuss the advantages and disadvantages of relevant mass 95 
spectrometry (MS) data acquisition workflows and data exploration approaches to confront the low 96 
analyte concentrations and ever-changing NPS market and will be supported using key research 97 
articles and illustrative practical examples. This tutorial is not intended to be an extensive review of 98 
the existing literature, but to give an insight into this timely topic and describes the experience 99 
gathered within different collaborations and projects. It also pays attention to new developments such 100 
as ion mobility separation (IMS) and the use of in-silico prediction tools to improve the identification 101 
capabilities.   102 
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2. Sample collection and sample treatment  103 
Well-designed protocols for sample collection and storage, and versatile sample treatment of pooled 104 
urine and wastewater are essential for getting data that provide meaningful information on NPS use. 105 
The collection of anonymous pooled urine samples from portable street urinals has recently 106 
demonstrated its utility to detect the use of recreational drugs, including NPS [18,19]. Generally, 107 
multiple samples are taken from various urine reservoirs, over a 12-hour period, and then mixed to 108 
form pooled urine samples. This sampling method can be applied in cities where stand-alone urinals 109 
are routinely used at weekends [19], but can also be used for monitoring specific night time settings 110 
or recreational events such as music festivals [20–24]. Sampling urine aliquots from urinals ensures 111 
the collection of anonymous and representative samples and results may reflect the direct use of NPS. 112 
Yet, some limitations are related to the fact that urinals are designed for male use only and normally 113 
have no ‘flushing’ mechanism [25]. Thus, the number of contributors to the samples is unknown and, 114 
although quantitative analysis is possible, the comparison of concentrations gives little additional 115 
insight rather than a qualitative overview of the actual use of a certain drug compared to the other 116 
substances quantified in that specific sample.  117 
Wastewater analysis may circumvent these limitations by providing anonymous population-118 
normalized information of an entire community and has recently been explored to gather information 119 
on NPS use [3,15,17,26,27]. The successful application of wastewater-based epidemiology for 120 
assessing spatial differences and temporal changes in illicit drug use has been demonstrated [28,29] 121 
where population-normalized data can be calculated taking into account the measured concentration, 122 
the daily flow rate of sewage and the number of people connected to the wastewater treatment plant 123 
(WWTP) [28,30]. Specific sampling protocols have been developed to obtain representative 24-hour 124 
composite wastewater samples collected at the inlet of a WWTP [28]. In addition, a standardized 125 
questionnaire facilitates the collection of relevant meta-data such as the daily flow rate of sewage and 126 
the number of people connected to the WWTP [31]. This meta-data allows quantitative population-127 
normalized information for a limited number of target NPS to be explored. The information provided 128 
by wastewater analysis can be integrated with existing epidemiological data because of the unique 129 
ability to provide objective, updated and nearly real-time information on drug use [16,32]. 130 
One sampling technique not yet fully explored but with potential for monitoring NPS in wastewater is 131 
passive sampling [33], which ensures the concentration of analytes from longer periods (days or 132 
weeks) and increases the possibility to detect substances with low prevalence of use. The main 133 
advantage is that passive samplers, consisting of polymeric-based sorbent material, deployed for 134 
longer periods, can accumulate trace analytes on the sorbent during this period. Moreover, as some 135 
NPS might be consumed sporadically (and thus might not always be present in wastewater), one does 136 
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not need to collect multiple wastewater samples, which all eventually need to be processed i.e. 137 
increasing labor costs. Hence, this technology offers practical and economic advantages for gathering 138 
long-term data. But it has also some challenges related to calibration and quantification, since they 139 
require knowledge about uptake and diffusion of the different substances and are subject to the 140 
variability associated with NPS stability and environmental factors (e.g., flow rates, biofouling) [33,34]. 141 
The uptake of target analytes on sorbent materials needs, therefore, to be determined prior to 142 
deployment in the sampling site.  143 
Stability of NPS is an important aspect of sample collection for both pooled urine and wastewater 144 
analysis. While specific stability studies in pooled urine samples are lacking, they have been carried 145 
out on urine samples for forensic toxicology purposes. Metabolites of synthetic cannabinoids have 146 
been shown to be stable up to 14 days when refrigerated [35]. Many synthetic cathinones, 147 
benzodiazepines and amphetamine-type derivatives are very stable under freezing (-20 °C) storage 148 
conditions for months-years. However, when stored at room temperature or even refrigerated, 149 
degradation of these compounds can occur within days [36–38]. Therefore, it is recommended to 150 
freeze pooled urine samples immediately upon collection to avoid degradation. Regarding 151 
wastewater, it has been shown that acidification to pH 2 improves the stability in both filtered and 152 
unfiltered wastewater for up to 14 days for a wide variety of NPS such as cathinones, 153 
phenethylamines, opioid-derivatives and amphetamine-like stimulants [39]. If samples cannot be 154 
acidified, it is recommended that they are kept either refrigerated (4 °C) or frozen (-20 °C) for no longer 155 
than one week prior to sample processing [39–42]. Several synthetic cannabinoids have been shown 156 
to be unstable at pH 2 and in raw wastewater i.e. the hydroxypentyl metabolites of JWH 122, AM 157 
2201, RCS-4 and JWH 073, while JWH 018 n-pentanoic acid, JWH 073 N-butanoic acid and JWH018 N-158 
5-hydroxypentyl were stable at room temperature for up to 24 hours [42]. Moreover, the use of 159 
sodium metabisulfite as a preservative has been recommended to improve the stability of synthetic 160 
cannabinoids [43]. 161 
A non-selective and versatile sample preparation protocol for the enrichment and clean-up of samples 162 
capable of retaining a wide range of NPS with broad physicochemical properties is preferred and 163 
applied by the vast majority of reported studies. Pooled urine samples are usually treated by 164 
performing a hydrolysis step to cleave drug-glucuronide conjugates with β-glucuronidase and 165 
arylsulfatase prior to solid-phase extraction (SPE), liquid-liquid extraction and/or dilute and shoot 166 
techniques [21,44,45], while wastewater samples do generally not require this hydrolysis step due to 167 
in-sewer deconjugation [46–50] and are normally filtered and solid-phase extracted [17], although a 168 
less labor-intensive and quicker preparation procedure following the QuECHeRS principle has also 169 
been applied [51]. In order to cover the broadest range of substances possible, multiple SPE cartridges 170 
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or cartridges consisting of several layers with different stationary phase chemistries can be used 171 
[27,52]. The use of more cartridges implies several separate extractions, yet these can be optimized 172 
to specific NPS categories of interest such as cathinones or synthetic cannabinoids [15,21]. Typically, 173 
cartridges containing polymeric-based SPE sorbents with reversed phase (RP) properties built of 174 
generic hydrophilic and lipophilic balanced monomers or strong cation-exchange mixed mode 175 
sorbents incorporating RP copolymers are used. For the latter, samples should be acidified to pH 2-3 176 
to ensure that the analytes are positively charged during extraction [53]. This especially aids the 177 
recovery of cathinones, amphetamine-like stimulants, opioid derivatives and phenethylamines 178 
[21,39,45,54,55]. Online SPE has also been utilized for a limited number of NPS using a RP cartridge, 179 
with satisfactory recovery (i.e. 70-120%) [56]. LLE has been shown to aid in the detection of synthetic 180 
cannabinoids in pooled urine [57] and wastewater [43,58]. For wastewater studies, it is important to 181 
note that the removal of the solid fraction through filtration can greatly affect the overall recovery of 182 
synthetic cannabinoids due to their lipophilicity. Therefore, when performing wastewater analysis, 183 
both the aqueous and particulate fraction should be extracted together for optimal recovery of 184 
cannabinoids.  185 
Although both pooled urine and wastewater analyses incorporate SPE, there is a much lower pre-186 
concentration factor needed for pooled urine, with initial volumes of 1-2 mL, due to the generally 187 
higher concentrations found [23,45,57]. Furthermore, lower pre-concentration results in less matrix 188 
effects and potentially an improved chromatographic performance. Higher pre-concentration factors 189 
in wastewater are commonly applied to deal with the very low concentrations of NPS expected in 190 
these samples. However, this can also result in strong matrix effects due to the pre-concentration of 191 
unremoved components present in the sample extract. Matrix effects are alterations of the MS signal 192 
(enhancement or suppression), which have been linked to co-eluting interferences such as proteins, 193 
lipids, sugars or salts, that affect the ionization process [59]. Frequently, isotopically labelled internal 194 
standards (ILIS) are used as surrogates and added to samples prior to processing (i.e., SPE) or analysis 195 
(in the case of dilute and shoot approaches applied in pooled urine analysis), to account for potential 196 
matrix effects, but also to correct for potential errors due to sample preparation. Ideally ILIS of the 197 
corresponding NPS are used as they are supposed to be affected in a similar manner as their non-198 
labelled counterparts. However, ILIS are often expensive and not always commercially available, 199 
especially in the case of NPS. Therefore, ILIS are regularly used to correct for several compounds 200 
[15,40]. Nevertheless, the performance of each ILIS for correcting matrix effects need to be carefully 201 
evaluated. When appropriate ILIS are unavailable, matrix effects may be minimized by applying an 202 
additional clean-up step, but also lower pre-concentration factors may occasionally be desired for 203 
some substances in order to reduce ionization suppression and increase their detection limit [27,60]. 204 
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In general, even when ILIS are available, a reduction of matrix effects is recommended for better 205 
precision, sensitivity and robustness in complex matrix samples [60].  206 
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3. Chromatographic separation 207 
Good chromatographic separation is important to reach the required levels of selectivity, sensitivity 208 
and identification power to monitor NPS through wastewater and pooled urine analysis. GC-MS has 209 
been applied for the determination of NPS in urine. However, because of the high levels of selectivity 210 
and sensitivity provided by this technique, it requires the derivatization of the analytes which results 211 
in a more time-consuming and less generic sample treatment [61,62]. Alternatively, LC-MS allows the 212 
determination of compounds with a broad range of polarity, low volatility and thermolability with the 213 
application of more generic sample treatment strategies. In addition, the aqueous nature of the 214 
matrices makes LC-MS fully compatible with the determination of NPS in wastewater and pooled urine 215 
samples [63]. 216 
Reverse-phase LC (RPLC) separates compounds within the range of low-polarity to non-polarity. 217 
Therefore, it seems to be the most suitable chromatographic technique to achieve generic and good 218 
chromatographic separation especially for wide-scope monitoring of NPS. Consequently, the vast 219 
majority of studies dealing with multi-residue methods in wastewater and/or pooled urine samples 220 
applied RPLC as the separation technique [13,23,25,64,65]. However, more polar (or ionic) substances 221 
such as amphetamine-like stimulants or synthetic cathinones and their metabolites, might require 222 
more specific methodologies. Recent developments in column chemistries and improvement in 223 
robustness of existing stationary phases allowed the analysis of more particular scenarios. Hydrophilic 224 
interaction LC (HILIC) is an alternative approach to effectively separate small and highly polar NPS. For 225 
example, Kinyua et al. [55] successfully developed a multi-residue methodology for the determination 226 
of 7 synthetic cathinones and amphetamine-like stimulants by means of HILIC separation. 227 
Additionally, enantiomeric analysis has also been explored for the determination of NPS [66–68]. 228 
Chiral NPS are usually consumed as racemic mixtures of different forms (i.e. with an enantiomeric 229 
fraction (EF) between the two forms of approximately 0.5), even though both forms might differ 230 
quantitatively and qualitatively in the pharmacological activity [69]. Therefore, enrichment of the R 231 
(or S) form, depending on the stereoselective metabolism in humans, is expected in biological samples 232 
[66]. Consequently, an EF found in wastewater or pooled urine samples deviated from the original EF 233 
value could help in distinguishing between human consumption and direct disposal of unused 234 
substances [66]. Other chromatographic techniques such as capillary chromatography and 235 
supercritical fluid chromatography (SFC) are promising strategies for the monitoring of NPS. The 236 
improvement in sensitivity provided by capillary chromatography, especially for the small 237 
amphetamine-like structures, revealed a technique to explore for this purpose [26]. Also, recent 238 
developments in commercially available instruments has seen an increase in applications of ultra-high 239 
performance (UHP) SFC - MS/MS, in particular using (sub)supercritical carbon dioxide (CO2) with 240 
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various organic additives as mobile phase [58,70]. One of the main advantages of UHPSFC compared 241 
to conventional UHPLC is its increased chromatographic efficiency and resolution [71] also permitting 242 
the separation of several NPS isomers with good results [72].  243 
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4. Quantitative target monitoring  244 
As discussed above, the determination of NPS can be challenging due to the large number of 245 
potentially relevant compounds and the low concentrations expected in samples, in particular when 246 
considering wastewater and pooled urine. In fact, due to the often low prevalence of use of individual 247 
compounds, concentrations of these substances are often orders of magnitudes lower compared to 248 
conventional illicit drugs (< 10 ng L-1) [55]. For this reason, targeted methods, specifically using LC-249 
MS/MS with QqQ or ion-trap mass analyzers, have been implemented for the reliable identification 250 
and quantification of selected NPS in urine and wastewater samples [15,17,73,74]. The development 251 
of such quantitative target methods, however, requires access to reference standards for precursor-252 
product ion transition selection in the Selected Reaction Monitoring (SRM) mode and MS parameters 253 
optimization. Identification and confirmation is achieved through the acquisition of at least two SRM 254 
transitions and matching of the retention time (RT) and ion-intensity ratios between the sample and 255 
reference standard [75,76]. The most sensitive SRM transition is commonly selected for the 256 
quantification at low concentration levels, whereas the second transition allows confident 257 
confirmation [26,40,46]. However, since NPS often retain high structural similarity, the risk of selecting 258 
common transitions is present and therefore the acquisition of more transitions (if feasible) is 259 
recommended to gain more confidence to the confirmation process. Hence, it is also important to 260 
understand fragmentation of each NPS as it allows the selection of specific product ions and avoid 261 
non-specific transitions such as a neutral loss of water or CO2[77]. The latter is especially relevant to 262 
minimize potential matrix interferences when analyzing NPS at low concentrations in highly complex 263 
matrices such as pooled urine and raw wastewater samples. Although quantitative target monitoring 264 
can be performed using LC-HRMS instruments, their application in the field is limited due to the 265 
generally lower sensitivity compared to low resolution MS/MS instruments [17]. Hence, the advantage 266 
of low-resolution instruments for quantitative analysis lies in the robustness, selectivity and sensitivity 267 
which can be achieved by monitoring these specific precursor-product ion transitions. Combined with 268 
their high scanning speed, these instruments can monitor many transitions almost simultaneously, 269 
and consequently high-throughput, multi-residue methods that include many targeted NPS 270 
biomarkers, can relatively easily be developed.  271 
Synthetic cathinones, phenethylamines, tryptamines and piperazine-derivatives have been 272 
quantitatively determined in pooled urine samples collected during weekends at specific night settings 273 
[25] or at music festivals [23]. Although data obtained from quantitative determination of NPS in 274 
pooled urine samples only gives an indication on the extent of use for an NPS compared to other 275 
substances found in a specific sample [23], these findings are still very valuable, as the application of 276 
these selective and sensitive target quantitative methods give high confidence and allows 277 
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confirmation of the NPS identified at low concentration levels. Synthetic cathinones are by far the 278 
most studied group of NPS in wastewater, followed by synthetic cannabinoids and phenethylamines. 279 
Studies using LC-MS/MS to monitor these substances have been carried out in Europe, Asia and 280 
Australia [15,17,26,39,40,78,79] and have shown spatial and temporal trends using population-281 
normalized data. Although LC-MS/MS methods are highly sensitive and multi-residue methods can be 282 
developed, they have a major drawback, namely reference standard materials need to be available 283 
for method development as previously highlighted. Given the high number of NPS that have been 284 
detected in the market and their transient nature, reference standards are mostly available for only a 285 
limited number of compounds. Moreover, by the time reference standards become available, these 286 
compounds might have already disappeared from the market as they may have been less popular or 287 
added to the lists of regulated substances and can thus not be sold legally anymore. Further 288 
exacerbating the determination of these substances is the extent of their metabolism. There have 289 
been studies carried out on the metabolism of NPS using human liver microsome incubations to better 290 
understand the metabolism of certain NPS [80–84]. In addition, recent advances in computing power 291 
have permitted the development of comprehensive knowledge based software to predict the 292 
metabolic fate [85,86]. However, reference standards of most of the metabolites proposed are not 293 
commercially available and therefore unsuitable for quantitative target monitoring. Thus, quantitative 294 
target LC-MS/MS methods, although indispensable to achieve the highest sensitivity needed for 295 
certain types of substances (e.g., fentanyl and its derivatives), need to be complemented by other 296 
analytical approaches which allow a quick and broader monitoring, without the necessity for reference 297 
standards. Although low-resolution mass spectrometry (LRMS), especially tandem MS instruments, 298 
are highly appreciated in quantitative analysis, its application to qualitative analysis and capabilities in 299 
detecting unknowns is, limited due to the relative low resolving power (approximately 1 Da) and low 300 
sensitivity in full scan mode [77]. The use of HRMS offers new possibilities in the determination of NPS 301 
as well as circumventing some of the limitations of LRMS.  302 
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5. Qualitative screening approaches  303 
HRMS presents strong potential for monitoring a large number of substances, due to its acquisition of 304 
accurate-mass full spectrum data at good sensitivity [63,77,87].  In order to facilitate the reading of 305 
this tutorial, terms that will be used in this section are defined below: 306 
Target screening based on HRMS allows the qualitative screening of NPS after data acquisition based 307 
on large databases, thus evading the pre-selection of analytes for method development and the need 308 
of reference standards. However, the information included in the database is limited by the availability 309 
of reference standards. When reference standards are available, information such as accurate masses 310 
of fragment ions, adduct formation and RT can be included, whereas only the elemental composition, 311 
exact mass and theoretical isotopic pattern can be included when no reference standard is available. 312 
Although the acquisition of data is performed in an untargeted way, the approach is considered 313 
targeted and generally known as suspect screening [77,87], since the search is based on a list of target 314 
compounds that can be expected to be found in the samples. An advantage of this approach is that 315 
retrospective analysis can also be performed at any time from the acquired data to search for 316 
substances initially not considered and included in the database, such as novel NPS or newly 317 
discovered metabolites [88,89]. It should, however, be noted that the detection of some substances 318 
might be restricted by the sample treatment, the chromatographic conditions or the ionization 319 
efficiency [90], since usually a generic analysis is performed and no optimization has been executed 320 
for the NPS included in the database.  321 
Non-targeted screening, without any selection of analytes, allows the investigation of any other NPS 322 
biomarker not included in the database. However, it implies an examination of each chromatographic 323 
peak and extensive investigation of its accurate mass spectrum. This process is challenging and time 324 
consuming and probably does not outweigh the rate of success in identifying of unknown NPS. 325 
Alternatively, the screening can be directed to discover related compounds of known NPS using 326 
characteristic mass spectral information and applying mass-defect filtering or common fragmentation 327 
pathways. 328 
As a starting point for researchers interested in undertaking qualitative screening of NPS by HRMS, 329 
the review article written by Hernandez et al. [63] describing different mass spectrometric strategies 330 
for the investigation of illicit drug biomarkers in wastewater is recommended. Although similar 331 
strategies and identification criteria can be applied for the investigation of NPS in pooled urine and 332 
wastewater, the challenges are different due to the rapid turnover in the NPS drug market creating a 333 
scenario with constantly moving analytical targets and the often lower prevalence of use compared 334 
to conventional illicit drugs. Moreover, the structural similarities of NPS and their metabolites often 335 
requires increased identification confidence in order to minimize reporting false positives. In the text 336 
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below, practical examples are given to discuss different data acquisition workflows and data 337 
exploration approaches to illustrate how HRMS can help in the confident identification of NPS in high-338 
complex pooled urine and wastewater samples. 339 
 340 
5.1. Acquisition modes for hybrid high resolution mass spectrometric systems 341 
The most commonly used HRMS analyzers are time-of-flight (TOF) and Orbitrap, which can be coupled 342 
with LC and possess high mass resolving power (> 20,000 Full Width at Half Maximum (FWHM)) and 343 
mass accuracy (< 5 ppm) for wide scope screening of NPS in pooled urine and wastewater [17,75,76]. 344 
However, hybrid configurations, such as quadrupole-TOF (QTOF) or quadrupole-Orbitrap (Q-Orbitrap), 345 
are nowadays more the standard than the exception as they considerably increase the potential of 346 
HRMS for screening NPS [20,21,27,44,52,91]. When working in MS/MS mode, it is possible to record 347 
accurate mass product-ion spectra of previously detected candidates and obtain relevant structural 348 
information to allow suspected NPS to be confidently identified or disregarded as false positives. 349 
However, the simultaneous accurate-mass acquisition of both full-spectrum and product-ion spectra 350 
data is preferable and collects accurate mass data of both the (de)protonated molecules and its 351 
fragment ions in a single acquisition and without the selection of precursor ions.  352 
In data-dependent acquisition (DDA) mode, the instrument first performs a “survey scan” from which 353 
the analyst chooses (or not) certain ions that fit specific criteria based on, for example, intensity 354 
thresholds. Ions for which these conditions are met, are then selected to be included in a list of 355 
preselected masses and fragmented to provide information-rich product ion scans. Unlike intensity 356 
thresholds, an inclusion (or exclusion) list allows large matrix interferences to be ignored, thereby 357 
facilitating the identification process and saving effort and time [27,52,63,92]. However, the size of 358 
the inclusion list (i.e., suspects to be fragmented) can adversely affect the cycle time of the instrument. 359 
Therefore, a decrease in the number of scans (or data points) across a chromatographic peak will 360 
occur, reducing its detectability. Moreover, any compound not included in the initial inclusion list 361 
cannot later be retrospectively analyzed, so the sample would have to be re-extracted and re-362 
analyzed. Yet, there is a way around this limitation, utilizing complementary targeted and untargeted 363 
DDA. This technique initially conducts an MS scan followed by targeted MS/MS using an inclusion list 364 
and then untargeted MS/MS on n-selected precursors. For example, analysts can look at MS/MS of 365 
the n most abundant precursor ions, which would be of great utility for samples with high levels of 366 
NPS such as seizure samples [14,93]. However, the generally low concentration of NPS found in pooled 367 
urine and wastewater might mask the detection of low abundant peaks, and therefore, many NPS may 368 
remain undetected [94]. 369 
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Data independent acquisition (DIA) allows the acquisition of accurate-mass full-scan spectra under 370 
different collision induced dissociation conditions within a single injection. This acquisition mode is 371 
known under different names depending on the manufacturer (e.g. All-ion-fragmentation (AIF), all-372 
ion MS/MS, MSE and broadband collision-induced dissociation (bbCID)), where all ions generated in 373 
the ion source are sent to the collision cell for fragmentation without precursor ion selection or any 374 
predefined selection criteria. This alternation between full-scan and untargeted MS/MS events at low 375 
collision energy (LE) and high collision energy (HE), respectively, allows one to obtain information 376 
relating to the accurate masses of the (de)protonated molecule as well as their fragment ions. 377 
Furthermore, it conserves highly valuable information on adducts and isotopes since the quadrupole 378 
works as an ion guide [63,77]. The main limitation of DIA is that spectra are non-selective and contain 379 
product ions for all ions formed in the ion source. Hence, the interpretation can be challenging, since 380 
co-eluting compounds or matrix interferences may “contaminate” the spectra, and makes it difficult 381 
to associate product ions with the correct (de)protonated molecule [14,95,96].  382 
Slightly different modes compared to the other DIA modes mentioned above in terms of specificity 383 
have been developed by manufacturers with the objective to have HE spectra approaching to MS/MS 384 
quality data. As an example, in Sequential Window Acquisition of all THeoretical fragment ion spectra 385 
(SWATH) mode, a TOF MS full scan at LE is acquired, alternated by SWATH experiments at HE obtaining 386 
MS/MS data by fragmenting only the (de)protonated molecules present in a much narrower window 387 
(e.g. 15 -25 m/z). In this way, SWATH can distinguish co-eluting compounds of different masses by 388 
having specific experimental mass fragmentation windows which filter out all masses not included in 389 
the specified mass range. This results in cleaner spectra, which facilitates identification [96,97]. This is 390 
a particular important point in the determination of NPS, which are notorious for the analytical 391 
challenges associated with common fragments. Figure 1 shows the utility of SWATH in differentiating 392 
two co-eluting NPS, butyryl fentanyl with m/z 351.2431 and furanylfentanyl with m/z 375.2067 in a 393 
spiked wastewater sample. In the full scan acquisition at LE, it can be observed from the individual 394 
extraction ion chromatograms (XICs) that the two NPS seemingly elute at 12.50 min (Figure 1A, top), 395 
with the mass spectra at this RT showing both masses (Figure 1A, bottom). However, when applying 396 
SWATH, the HE experiments carried out at different mass windows (m/z 340.2 – 357.4; Figure 1B and 397 
m/z 372.6 – 389.8; Figure 1C) allowed them to be distinguished by extracting the mass of each of these 398 
fentanyl derivatives in their corresponding acquisition window. With the mass of butyryl fentanyl and 399 
furanylfentanyl falling within separate experiments, they can be individually extracted and identified 400 
using cleaner spectra. This exemplifies the power of this acquisition mode in the elucidation of NPS.   401 
 402 
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[Insert Figure 1 here: Identification of two co-eluting NPS, butyryl fentanyl (m/z 351.2431) and 403 
furanylfentanyl (m/z 375.2067) in a spiked wastewater sample using Sequential Window 404 
Acquisition of all THeoretical fragment ion spectra (SWATH). (A) overlapping extraction ion 405 
chromatograms (XICs) of the two NPS with chromatographic peaks eluting at 12.50 min (top); 406 
full scan acquisition mass spectra with low collision energy (LE) (10 V) at retention time 12.50 ± 407 
0.10 min (bottom). (B) SWATH mass window m/z 340.2-357.4, XIC at m/z 351.24 (middle) and 408 
high collision energy (HE) mass spectra (bottom); (C) SWATH mass window m/z 372.6-389.8, XIC 409 
at m/z 375.21 (middle) and HE mass spectra (bottom)] 410 
 411 
5.2. Suspect screening 412 
Suspect screening approaches usually take advantage of home-made databases. However, the 413 
information included therein is limited by the availability of reference standards, as previously 414 
explained. When no reference standard is available, the minimum suggested requirements for a 415 
tentative identification is the accurate mass of the (de)protonated molecule and, at least, one 416 
significant fragment ion together with the corresponding isotopic pattern. This is in the line with 417 
proposed quality procedures recommended in other research fields [76,98]. The observed fragments 418 
need to be in accordance with the chemical structure and, preferably, in agreement with previously 419 
reported data in scientific literature or online spectral databases [27,52,99,100]. Ideally, reference 420 
standards are available, and information such as accurate masses of fragment ions, adduct formation 421 
and RT can be included, which allow unequivocal identification. However, this entails high costs due 422 
to the high number of compounds and, therefore, huge efforts have been devoted, in the recent years, 423 
to develop community-made or online mass spectral databases for NPS.  The best known databases 424 
are NPS Data Hub [101] and HighResNPS [102,103] with more than 2800 and 3350 entries, respectively 425 
(date accessed: 26 June 2020). The HighResNPS library currently has active users from more than 10 426 
laboratories around the world with the intention to ensure up-to-date analytical information from the 427 
moment a specific NPS becomes available to a given participating laboratory [102]. These libraries are 428 
available to help and facilitate the screening of NPS and their metabolites [101,104–106].  429 
In most laboratories, a suspect screening based on large home-made databases is often the first step 430 
for monitoring samples. Due to the high number of NPS and metabolites, the rapid transience of these 431 
compounds on the market, high costs and limited availability of reference standards, home-made 432 
databases are normally built of merely accurate masses of the (de)protonated NPS and fragment ions. 433 
Yet, the low concentration levels of NPS present in combination with strong matrix interferences 434 
makes the tentative identification of NPS challenging and remark often the necessity to perform some 435 
additional research or experiments to increase the confidence in the tentative identification. As an 436 
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example, Figure 2 shows the tentative identification of 4-chloro-α-pyrrolidinopropiophenone (4-437 
chloro-α-PPP) in a pooled urine sample. Its protonated molecule, the isotopic information related to 438 
the presence of one chlorine atom and at least one fragment ion was observed at accurate mass 439 
(Figure 2A). However, a known and abundant fragment of 4-chloro-α-PPP at m/z 167.0258 [107] 440 
showed an undue high mass error (+143 ppm) under the initial screening conditions, which made the 441 
tentative identification of this NPS questionable. By increasing the mass resolution of the Orbitrap MS 442 
from 20.000 to 35.000 FWHM and zooming in the m/z range of the fragment, it was possible to 443 
distinguish three peaks at m/z 167, one corresponding to the fragment ion m/z 167.0258 (+5.3 ppm) 444 
of 4-chloro-α-PPP (Figure 2B, bottom). This allowed more confidence to be gained in the 445 
identification. Subsequently, the feature could be identified as 4-chloro-α-PPP by means of a reference 446 
standard. The latter is pivotal for the confirmation of the identity of the NPS. However, by using this 447 
approach, laboratories do not need to purchase all reference standards a priori to the analysis [108] 448 
and could prioritize those NPS for which more reliable evidence is obtained. 449 
 450 
[Insert Figure 2 here: Tentative identification of 4'-chloro-α-pyrrolidinopropiophenone (4-chloro-α-451 
PPP) in a pooled urine sample. (A) Extracted ion chromatogram of 4-chloro-α-PPP and 37Cl 452 
isotope (top); Product ion mass spectra of [M+H]+ at m/z 238.10 (bottom). (B) Structure of 4-453 
chloro-α-PPP (top); Zoom in the range of fragment ion with m/z 167 at resolution (R) of 454 
35.000 Full Width at Half Maximum (FWHM) (bottom)] 455 
 456 
Positional isomers or homologues are frequently the first choice to substitute banned NPS [109]. 457 
Hence, NPS often have only minor modifications to a backbone structure and the structural similarities 458 
of NPS and their metabolites are often reflected by their common fragmentation pathways, this poses 459 
one of the principal challenges in suspect screening strategies. As an example, the analysis of a raw 460 
wastewater sample showed a chromatographic peak at 4.51 min giving a positive hit for the isomers 461 
α-methyltryptamine (AMT) and 5-(2-aminopropyl)indole (5-IT) based on the accurate mass of their 462 
protonated molecule and their fragment ions (Figure 3A). These two isomers share the same chemical 463 
backbone with the only difference being the position of the substituent (Figure 3B and 3C, top). The 464 
following MS fragment ions were found: m/z 158.0954, m/z 143.0724, m/z 132.0799, m/z 117.0577 465 
and m/z 115.0541, with the most abundant fragment at m/z 143.0724 (Figure 3A, bottom). The only 466 
difference, described in the literature, between the spectra of AMT and 5-IT resides in the relative 467 
intensities of the fragment ions [110]. The most intense fragment ion of 5-IT has an m/z of 130, 468 
whereas the most abundant fragment ion for AMT corresponds to m/z 143. This slight difference in 469 
the fragmentation pattern (i.e. intensities) gave more confidence in the tentative identification of AMT 470 
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instead of 5-IT in this sample. Therefore, AMT was synthesized and a reference standard of 5-IT was 471 
donated by a collaborating laboratory. When comparing that empirical data to AMT and 5-IT reference 472 
standard MS fragment ions (Figure 3b and 3c, bottom), it can be observed that both substances share 473 
the same fragment ions (in nominal mass; m/z 143, m/z 130, m/z 117 and m/z 115) coinciding with 474 
the fragment ions observed in the sample, but that AMT indeed show a more abundant fragment ion 475 
with m/z 143. This gave more confidence in the positive identification of this NPS and together with 476 
its RT, AMT could finally be confirmed. 477 
 478 
[Insert Figure 3 here: Identification of α-methyltryptamine in a raw wastewater sample using QTOF 479 
MS. (A) feature detection of m/z 175.1235 at 4.51 min (top, insert) together with the low 480 
collision energy (LE) spectra (top) and high collision energy (HE) spectra with emphasis on m/z 481 
130-145 (grey areas) (bottom); (B) Structure, fragment ions, LE and HE spectra of α-482 
methyltryptamine; (C) Structure, fragment ions, LE and HE spectra of 5-(2-aminopropyl)indole] 483 
 484 
5.3. In-silico approaches 485 
In some cases, the instrument-specific parameters (i.e. accurate mass ions and isotopic patterns) do 486 
not suffice to tentatively propose a chemical structure, and, therefore, additional studies are required. 487 
For that purpose, predictive models have been used to filter out false positives and increase the 488 
confidence of compound identification when reference standards are unavailable or no information 489 
is within reach in previously reported data [27,111,112]. Aalizadeh et al. developed a RT prediction 490 
model using Quantitative Structure-Retention Relationships (QSSR) and Support Vector Machines 491 
(SVM) to model the RT data for both HILIC and RPLC with high accuracy [111]. A different approach 492 
was proposed by Bade et al. considering the application of Artificial Neural Networks (ANNs) for the 493 
development of a RT predictor for gradient-RPLC using a dataset of more than 500 compounds with 494 
an predictor accuracy of ±2 min [112]. Such RT predictive tools are highly valuable for the 495 
determination of NPS in complex matrices as demonstrated by Diamanti et al. [27]. Since the 496 
availability of reference standards is limited, the suspect screening of NPS usually results in many 497 
candidate structures because of the structural similarity of many NPS, as for example, in the case of 498 
the two isomeric phenethylamines 3,4-methylenedioxy-N-hydroxyethylamphetamine (MDHOET) and 499 
N-hydroxy-N-methyl-3,4-ethylenedioxyamphetamine (EFLEA). The predicted RT using a QSSR 500 
predictor model matched the one for MDHOET and discarded the one for EFLEA, thereby reducing the 501 
number of candidates and increasing the confidence in the tentative identification of MDHOET in 502 
influent wastewater from Athens [27]. In-silico fragmentation tools, such as the MetFrag software, are 503 
pivotal in a suspect screening workflow. This software generates a predicted fragmentation of 504 
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molecules based on their structure and compare it to the empirical data gathered proposing a list of 505 
fitting candidates together with a scoring parameter [113,114]. However, it is common that many 506 
structurally related substances can be assigned to the empirical data with a similar score value [113], 507 
which is a drawback particularly for the investigation of NPS because of the similarity of several 508 
substances.   509 
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6. Ion mobility separation coupled to high resolution mass spectrometry 510 
The recent development of the hyphenation of IMS with LC-QTOF MS instruments (LC-IMS-QTOF MS) 511 
represents an innovative tool for their application in target and non-targeted screening strategies. IMS 512 
separates ions depending on their size, shape and charge in a gas phase, (usually nitrogen or helium), 513 
and in the presence of an electric field [115]. Ion separation occurs in the millisecond time scale, 514 
making it compatible with fast TOF MS acquisitions [116]. The time an ion takes to travel through the 515 
mobility cell i.e. the drift time (DT), adds an extra dimension to the obtained chromatographic RT and 516 
accurate mass, which results in increased selectivity and improved identification, particularly in DIA 517 
modes [116,117]. The increased selectivity is translated into much cleaner and higher-quality spectra 518 
than conventional HRMS DIA spectra, since (de)protonated molecules and fragment ions of interest 519 
with the same DT can be aligned and separated from co-eluting matrix components. Although data 520 
sets inherently become more complex and more comprehensive, the utilization of IMS-HRMS 521 
instruments does not overcomplicate the data revision process thanks to the four-dimensional 522 
automatic feature detection. This allows the software to both deconvolute peaks based on 523 
chromatographic and MS data and align ions with the same RT and DT into unique features. Thus, LE 524 
and HE spectra are DT filtered for the deconvoluted ions (i.e. for each ion detected in the LE spectra 525 
its DT is used to correlate it with the fragment ions obtained in the HE spectra). Cleaner spectra can 526 
also be obtained by improving the chromatographic separation. Although improvements in the quality 527 
of the spectra often relies on spectral discrimination of the compounds, a good chromatographic 528 
separation is recommended especially when analyzing complex matrices such as pooled urine and 529 
wastewater that contain many co-eluting interferences. Yet, IMS provides an extra dimension of 530 
separation which fits between chromatography and MS and results in cleaner spectra, but without 531 
increasing the chromatographic run time or mass resolving power. 532 
A further advantage of IMS is that Collision Cross Section (CCS) values can be derived from the DT and 533 
represent the surface of the sphere created by the ion when moving in the gas phase. Unlike DT, CCS 534 
is an instrument independent value, provided that the same drift gas and ion mobility calibration 535 
standards are used [116,118,119]. The importance of CCS values relies on the fact that they are robust 536 
across multiple platforms (i.e. deviation up to 2%), independent of the chromatographic conditions 537 
used and not affected by matrix composition [118–120]. CCS values depend on the calibration 538 
procedure applied, and the deviation between instruments is caused by the slight experimental 539 
variations in room temperature, gas pressures and other hardware settings. Hence, CCS is a parameter 540 
that can give support to MS-based compound identification in addition to RT, m/z, isotopic pattern 541 
and fragment ions. Finally, IMS enables, in theory, the separation of isomeric compounds not 542 
previously resolved using LC, since they are expected to have a different mobility in the drift cell, and 543 
21 / 44 
 
therefore different CCS values [121,122]. Although there is a relationship between the m/z and CCS, 544 
Bijlsma et al. [123] showed that a range of 35 Å2 could be observed for molecules of approximately 545 
300 Da, therefore, demonstrating that no direct correlation between m/z and CCS could be established 546 
and that thus IMS may separate isomers. 547 
 Figure 4 illustrates the benefits of IMS in terms of higher-quality spectra in DIA MS/MS events. In this 548 
example, a positive finding of ketamine in a wastewater sample is shown using an ion mobility 549 
separation QTOF MS (Vion from Waters). When searching for ketamine (with m/z 238.0993 ≤ 5ppm) 550 
a chromatographic peak at a RT of 3.33 min was observed (Figure 4A, top (yellow arrow)). The 551 
corresponding conventional DIA MSE spectra (LE and HE) show many ions when no DT alignment is 552 
applied (Figure 4B, top) resulting in a base peak with m/z 263.1386, which does not correspond to 553 
ketamine (i.e. m/z 238.0993, highlighted in green). However, when applying the IMS MSE acquisition 554 
mode (HDMSE, High-Definition MSE), several co-eluting ions at 3.33 min are separated in the mobility 555 
cell, illustrated as red or black dots in Figure 4A, bottom. The DT of the ion with m/z 238.0993 was 556 
4.89 ± 0.20 ms and the corresponding fragment ions in this range, the blue highlighted areas, can be 557 
aligned. All other ions outside this area are filtered out, which results in much cleaner and easier to 558 
interpret spectra (Figure 4B, bottom). Despite the presence of some co-eluting interferences with 559 
similar DT, the resulting spectra contains fragment ions which could be primarily assigned to ketamine 560 
[124]. 561 
 562 
[Insert Figure 4 here: Identification of ketamine in a wastewater sample using IMS QTOF MS. (A) 563 
feature detection of m/z 238.0993 at 3.33 min and drift time (DT) 4.89 ms, yellow arrow (top); 564 
co-eluting ions at 3.33 min illustrated as red or black dots and separated by DT. Blue highlighted 565 
areas are the DT ranges of 4.89 ± 0.20 ms at m/z 238.0993 at low collision energy (LE) and high 566 
collision energy (HE) (bottom). (B) LE and HE mass spectra without IMS DT alignment (top); LE 567 
and HE mass spectra with IMS DT alignment (bottom)]  568 
 569 
The additional cleaning of spectra provided by IMS is of particular relevance for the determination of 570 
NPS in challenging matrices such as wastewater or pooled urine where thousands of naturally 571 
occurring compounds can hamper the identification of these substances at the low concentration 572 
levels expected. Moreover, since the CCS value of a certain molecule is not affected by matrix 573 
composition, their utilization as an additional identification point in the determination of NPS pushes 574 
IMS-HRMS as a promising technique in the monitoring of these substances [125,126]. Therefore, the 575 
development of home-made or collaborative on-line databases including ion mobility data will 576 
enhance the efficiency of target NPS screening. However, as has been discussed earlier, due to the 577 
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lack of analytical standards for most of the NPS and metabolites and the still sparse accessibility to 578 
IMS-HRMS instruments in research centers, the availability of CCS values for these substances is still 579 
very limited. Hence, in-silico predictive tools similar to those for RT and MS fragmentation may help 580 
to increase the confidence in the identification of tentative candidates. Several data-driven CCS 581 
predictor systems have been developed for the prediction of CCS values for small molecules [123], 582 
pharmaceuticals and drugs of abuse [127] and metabolites [128]. As an example, the predictor 583 
reported by Bijlsma and Bade et al. [123] was developed using 205 CCS values for small molecules 584 
including pharmaceuticals, pesticides and drugs of abuse with ANNs for modelling the ion mobility 585 
data. Although the empirical variability of CCS measurements across instruments for a certain 586 
molecule is known to be up to 2%, with the developed CCS predictive model, the maximum deviation 587 
at the 95% confidence interval was only 6%. Mollerup et al. [127] were able to reduce the deviation 588 
in the predicted CCS to a 4%, consequently increasing the accuracy of the model. In the case of the 589 
predictor model developed by Zhou et al. [128], support vector regression was applied to the 590 
development of predictive models for different molecular adducts with median relative errors of 591 
approximately 3%. Regardless of the predictive model applied for the prediction of CCS, the utilization 592 
of these strategies facilitates the tentative identification of NPS in suspect screening strategies [125], 593 
especially when combined with RT and MS fragmentation predictive tools.   594 
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7. Future perspectives  595 
The determination of NPS in pooled urine and urban wastewater has shown several challenges due to 596 
distinct factors as discussed in this manuscript. Current analytical instrumentation based on LC 597 
combined with LRMS and HRMS and the application of complementary data acquisition workflows 598 
and data exploration approaches helps to circumvent or confront certain barriers. However, more 599 
research related to NPS biomarkers is required and several trends in analytical chemistry, which is 600 
under continuous development, can be highlighted: 601 
 602 
i. NPS biomarker selection. The high number of existing NPS and the constant introduction of new 603 
compounds on the drug market creates a dynamic scenario of moving target biomarkers. Hence, 604 
monitoring of all NPS is complex and efforts could therefore be initially focused on NPS which are 605 
relatively high-dosed or frequently consumed and excreted (partly) unchanged such as 606 
amphetamine-like substances and cathinones. Especially since scant information on NPS 607 
pharmacokinetics is currently available, which complicates the choice of suitable biomarkers 608 
(parent substance or urinary metabolites) [129,130]. This is particularly relevant for synthetic 609 
cannabinoids and compounds like NBOMes that are highly metabolized in the human body 610 
[42,131,132] and for synthetic opioids that are consumed at very low doses [39], leading in both 611 
cases to very low concentration levels of the corresponding biomarkers in urine and, 612 
consequently, in wastewater. However, there are some published works on the metabolism of 613 
NPS [80–84] and different computational tools exist that predicts the metabolic fate of chemicals 614 
[86,87]. Although the proposed metabolites therein are generally not commercially available for 615 
quantitative target monitoring, these compounds should be included within screening databases 616 
as well as aiding in retrospective data analysis to ensure that the most appropriate analytical 617 
targets are investigated.  618 
ii. Sample collection, storage and treatment of pooled urine and wastewater is pivotal for getting 619 
meaningful information on NPS use. Pooled urine analysis of samples collected from portable 620 
toilets and urinals give an informative snapshot of the NPS used, but is often limited to men only 621 
and it is difficult to extrapolate results to the total number of toilet users. All-gender toilets with 622 
an improved design, complying specific technical requirements like a flushing mechanism and a 623 
visitor counter could circumvent these limitations in future studies. Currently, daily composite 624 
wastewater samples are more representative and analysis provides population-normalized 625 
quantitative information on NPS. A best practice protocol to collect representative wastewater 626 
samples of an entire community is available [32] to ensure the comparability of results from 627 
different countries. However, wastewater is more diluted compared to pooled urine resulting in 628 
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lower concentrations, which may complicate the detection of some NPS. Passive sampling 629 
increases the possibility to detect substances with low prevalence of use, because of the sampling 630 
and concentration of analytes over a longer period of time. Yet, passive sampling also merely 631 
gives a snapshot and has several limitations that need to be overcome or optimized as previously 632 
described. Recent developments, using diffusive gradients in thin films which, in contrast to 633 
conventional samplers, consist of a diffusive and binding gel and are exposed to the medium, are 634 
less dependent to hydrodynamic condition (e.g.  flow rates) and can hence overcome some of 635 
the limitations encountered with conventional passive samplers  [133,134].  636 
A relevant requirement for an NPS biomarker is its stability in pooled urine and wastewater in 637 
order to avoid any loss that can prevent detecting its use. Further work need to be addressed to 638 
test biomarkers stability and potential degradation or transformation in raw wastewater  and 639 
urine [39–41,94]. Until more information is available, it is recommendable to store samples in the 640 
dark at -20 °C directly after sample collection in order to minimize possible degradation. 641 
Sample treatment is very important to improve detection. However, a versatile sample treatment 642 
to retaining a wide range of NPS is not always feasible and specific treatments for certain NPS 643 
classes such as synthetic cannabinoids and synthetic opioids (i.e. high potency NPS such as 644 
fentanyl) need to be developed.  645 
iii. Good chromatographic separation might seem less important when coupled to highly sensitive 646 
and selective mass spectrometers, although it can be essential in the detection and identification 647 
of NPS. Taking into account the many isomers or structurally related compounds and the often 648 
strong matrix effects, more effort could be put into chromatographic separation in future work. 649 
HILIC and enantiomeric analysis have demonstrated a strong potential to move a step forward 650 
into a more comprehensive determination of NPS in wastewater and pooled urine. Capillary 651 
chromatography and UHPSFC-MS/MS have also been explored. Yet, some concerns have also 652 
been raised related to the robustness of the technique to routinely analyze complex matrices. 653 
Future developments in terms of more robust column chemistries will open a new scenario for 654 
the monitoring of NPS. Additionally, UHPSFC has the potential to combine the advantages of LC 655 
and GC, thus improving analytical capabilities of laboratories dealing with the determination of 656 
NPS. 657 
iv. Highly sensitive targeted methodologies based on LRMS will continue to play an important role 658 
in monitoring NPS use, particularly for those compounds which have established a niche market 659 
and/or are highly potent and require low detection limits. In addition,  complementary suspect 660 
screening approaches based on large home-made databases, including many substances for 661 
which reference standards are not available, will remain the common practice for the foreseeable 662 
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future. Furthermore, the improved sensitivity and quantitative capabilities of HRMS instruments 663 
combined to multi-stage off-line or on-line solid-phase extraction allow achieving targeted 664 
quantitative and qualitative screening analyses in a single run, thus overcoming the need of having 665 
two distinct instruments/methods [27]. Similarly, machine learning algorithms used to relate peak 666 
area of features recorded in HRMS analyses, chromatographic and mass spectrometric conditions 667 
to concentrations, might overcome the need for reference standards to obtain an (indicative) 668 
information about analyte concentrations in measured samples [135]. Qualitative information 669 
about the presence or absence of given NPS in wastewater is informative and studies have shown 670 
some spatial and temporal trends [23,27,136], but only quantitative data can provide absolute 671 
comparisons by showing changes in community prevalence through concentrations or mass loads.  672 
v.  Non-target screening remains predominantly unexplored for the identification of NPS in pooled 673 
urine or wastewater. A genuine non-target screening without any selection of analytes to be 674 
searched is a very challenging and time consuming process and a more successful strategy would 675 
be the application of non-target screening directed towards the discovery of compounds 676 
structurally related to known NPS. In this case, the higher concentrations generally present in 677 
pooled urine makes this matrix most interesting for this approach. The expected improvements 678 
for the forthcoming years in the mass-resolving power of HRMS instruments in combination with 679 
higher scan-speed will allow the acquisition at higher mass resolution with more efficient 680 
chromatography. This development in instrumentation will improve sensitivity and can also be 681 
very useful to differentiate between isobaric compounds (i.e. compounds with the same nominal 682 
mass but different chemical formula and thus different exact mass). Moreover, improved mass 683 
resolving power does not only improve the separation of parent compounds, but can also help 684 
finding characteristic fragment ions and gain confidence in the obtain identification. Furthermore, 685 
improvements in software tools for peak picking and data deconvolution (i.e. the capability to find 686 
chromatographic peaks of compounds and to obtain high quality spectra) will aid to a successful 687 
identification of NPS, but the knowledge of basic rules in mass fragmentation and thus the 688 
expertise of the mass spectrometrists should not be overlooked in both suspect and non-target 689 
screening.  690 
vi. The rapid transience of NPS in the drug market as well as the limited availability of reference 691 
standards for both NPS and known metabolites poses an analytical challenge for the full 692 
confirmation of substances detected. Therefore, the development and continuous updating of 693 
collaborative and public NPS mass spectral databases will smooth the identification process since 694 
contributors and users to those databases will have access to empirical information without the 695 
need of having the reference standards in their own laboratories. Hence, the number of false 696 
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positive identification (based on suspect and non-target screening) will be reduced since tentative 697 
identifications will be supported by empirical data from other researchers.  698 
vii. As is the case with online databases, prediction tools ease the tentative identification of NPS. The 699 
development of metabolic, RT and CCS predictive models represent a turning point in the 700 
investigation of NPS. The continual development of more accurate and refined predictive models 701 
will make prediction tools even more powerful for the application of NPS consumption – 702 
particularly the complexity associated with structural similarities among NPS families. The small 703 
differences in the chemical backbone for most NPS classes and consequently similar 704 
physicochemical properties often make the current predictive tools less than ideal due to the 705 
analogous outcome obtained from the prediction.  706 
viii. Retrospective analysis will continue to play an important role in uncovering trends in NPS 707 
consumption. HRMS analyses allow analysts to continually explore samples, without the time 708 
expense associate with re-extracting and re-analyzing samples. Reprocessing samples should be 709 
performed periodically, which can be a laborious task. Nevertheless, it is an interesting tool, as 710 
‘new’ NPS and metabolites are found, standards become more available and predictive techniques 711 
become more commonplace, retrospective analyses can be performed to better reveal 712 
community use of NPS.  713 
ix. Ion mobility separation coupled to HRMS has arisen as a useful technique and it is expected that 714 
it will gain in popularity. The cleaner and higher-quality mass spectra as well as the increased 715 
sensitivity of the instruments facilitates the identification process of NPS at low concentration 716 
levels and in complex wastewater or pooled urine samples. Future improvements will be related 717 
to the resolution of IMS instrument to enhance the separation of isobaric or isomeric substances 718 
that cannot be previously resolved by chromatography.   719 
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8. Conclusions 720 
Comprehensive analytical strategies can be applied to investigate NPS in pooled urine and 721 
wastewater, from quantification of target biomarkers to the detection and (tentative) identification 722 
of new substances and metabolites. The investigation of NPS in pooled urine and wastewater is a 723 
subject of current interest because, integrated with additional epidemiological information, it can be 724 
a useful tool for a comprehensive assessment of NPS use. In this context, data triangulation with 725 
traditional indicators, such as public surveys, online forums, data of drug testing services, police 726 
seizures and forensic analyses, is pivotal to gauge community consumption. Thus, the analysis of 727 
pooled urine and wastewater can complement other data and provide a more complete picture of 728 
community consumption.  729 
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Figure captions 1243 
Figure 1: Identification of two co-eluting NPS, butyryl fentanyl (m/z 351.2431) and furanylfentanyl 1244 
(m/z 375.2067) in a spiked wastewater sample using Sequential Window Acquisition of all 1245 
THeoretical fragment ion spectra (SWATH). (A) overlapping extraction ion chromatograms 1246 
(XICs) of the two NPS with chromatographic peaks eluting at 12.50 min (top); full scan 1247 
acquisition mass spectra with low collision energy (LE) (10 V) at retention time 12.50 ± 0.10 1248 
min (bottom). (B) SWATH mass window m/z 340.2-357.4, XIC at m/z 351.24 (middle) and high 1249 
collision energy (HE) mass spectra (bottom); (C) SWATH mass window m/z 372.6-389.8, XIC at 1250 
m/z 375.21 (middle) and HE mass spectra (bottom). 1251 
Figure 2: Tentative identification of 4'-chloro-α-pyrrolidinopropiophenone (4-chloro-α-PPP) in a 1252 
pooled urine sample. (A) Extracted ion chromatogram of 4-chloro-α-PPP and 37Cl isotope (top); 1253 
Product ion mass spectra of [M+H]+ at m/z 238.10 (bottom). (B) Structure of 4-chloro-α-PPP 1254 
(top); Zoom in the range of fragment ion with m/z 167 at resolution (R) of 35.000 Full Width at 1255 
Half Maximum (FWHM) (bottom). 1256 
Figure 3: Identification of α-methyltryptamine in a raw wastewater sample using QTOF MS. (A) feature 1257 
detection of m/z 175.1235 at 4.51 min (top, insert) together with the low collision energy (LE) 1258 
spectra (top) and high collision energy (HE) spectra with emphasis on m/z 130-145 (grey areas) 1259 
(bottom); (B) Structure, fragment ions, LE and HE spectra of α-methyltryptamine; (C) Structure, 1260 
fragment ions, LE and HE spectra of 5-(2-aminopropyl)indole. 1261 
Figure 4: Identification of ketamine in a raw wastewater sample using IMS QTOF MS. (A) feature 1262 
detection of m/z 238.0993 at 3.33 min and drift time (DT) 4.89 ms, yellow arrow (top) (*70 1263 
µs/scan); co-eluting ions at 3.33 min illustrated as red or black dots and separated by DT. Blue 1264 
highlighted areas are the DT ranges of 4.89 ± 0.20 ms at m/z 238.0993 at low collision energy 1265 
(LE) and high collision energy (HE) (bottom). (B) LE and HE mass spectra without IMS DT 1266 
alignment (top); LE and HE mass spectra with IMS DT alignment (bottom).   1267 
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